DANIEL MARSHALL: Open Payments
NPI 1073248829 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$518 in 25 payments from 8 companies in 2025. Trend: 2023 $34 · 2024 $557 · 2025 $518
Food & beverage: $518
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $251 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Alkermes, Inc. | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Corium, LLC | 3 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: FANAPT, REXULTI, ARISTADA, AUSTEDO XR, Azstarys, INGREZZA, Dyanavel XR, Auvelity.
Industry payments across ID — which companies pay providers there.
